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The questions of whether, when, and how much to provide 
of a health care intervention are central to decision making 
across all levels of health care, from government through 
to individual clinicians. A recent Editorial in Australian 
Journal of Physiotherapy declared that the benefit-harm 
trade-off method (Barrett et al 2005) was a ‘clearly superior’ 
approach to determine whether effects of an intervention 
were clinically important (Ferreira and Herbert 2008). This 
is a contentious position deserving further exploration.
The benefit-harm trade-off method involves presenting 
patients with a series of hypothetical scenarios where the 
benefits of an intervention are varied while costs, harms, and 
inconveniences of the intervention are held constant. From 
the perspective of a health economist, the point at which 
a clinical effect is sufficient to warrant implementation 
could be argued as being the point at which the benefits 
obtained from its provision outweigh the costs. The cost-
benefit analysis approach directly addresses this question 
by (to simplify) placing a monetary value on the costs 
incurred consequent to provision of the intervention, and 
weighing this against a monetary valuation of the health 
benefits gained (Drummond et al 1993). To this point, the 
underlying concept of cost-benefit analysis is consistent with 
that of the benefit-harm trade-off method. However, cost-
benefit analysis is typically undertaken from a ‘societal’ 
perspective in line with welfare economic theory rather 
than from the ‘patient’ perspective, meaning that a broader 
set of costs and benefits are considered. Patients are rarely 
the sole stakeholders and decision makers in decisions 
about health care provision and utilisation. The decision to 
make available particular health care services is commonly 
made by health care administrators and professionals rather 
than by individual patients. The expectations of individual 
patients also cannot be expected to represent the views of 
the other stakeholder groups that fund healthcare programs 
such as governments, insurance companies, and the tax-
paying public.
The benefit-harm trade-off method requires patients 
to understand fully the costs and consequences of the 
scenarios put before them to be able to make an informed 
decision. There is a balance between depth of explanation 
and potential for participants to remember and integrate 
all of this information into their decision-making process. 
Hence this approach is likely to have limitations when 
applied to patient populations with limited cognitive 
processing capacity, or for evaluation of complex health 
care interventions, or interventions with a range of potential 
side effects or benefits.
So, what value then are distribution- and anchor-based 
approaches to calculating a minimally important difference? 
Anchor-based approaches attach implicit ‘meaning’ to units 
of change on a measurement scale by explaining what impact 
this amount of change has on the ‘anchoring’ variable. This 
can be important from multiple stakeholder perspectives. 
Hypothetically, an increase of 1 point on a 10-point visual 
analogue scale of cancer-related fatigue may be associated 
with a 4 hour reduction in the number of hours per week that 
person is able to work at their occupation. For an employer, 
this means half a day in lost production. For a government, 
less economic activity results in less taxation revenue to 
fund healthcare and other services. Another example is 
that a 10-point change in the Functional Independence 
Measure corresponds to a halving of the time required to 
care for a person following stroke (Granger et al 1993). 
Distribution-based approaches are useful adjuncts to anchor-
based approaches. Rather than providing a new clinical 
meaning, they are useful for confirming the rationality of 
application of the clinically important differences selected 
through anchor-based approaches. If the Standard Error of 
Measurement of our cancer-related fatigue scale = 2, then 
we would have 68% confidence that an individual patient’s 
true score fell within + 2 points and 95% confidence that the 
individual’s true score fell within + 4 points of the observed 
score. Thus, if we observed that an individual reduces their 
level of cancer-related fatigue as a result of our intervention 
by a value of 1 point, we must consider whether we have 
observed a real, clinically important change, or simply 
measurement error.
There are many potential applications of a clinically 
important difference developed through anchor-and 
distribution-based approaches to assist with decision 
making. These are not limited by the patient population, 
complexity of intervention, or breadth of benefits and side 
effects. Despite the concerns we have raised regarding the 
benefit-harm trade-off method, we view it as also being a 
potentially useful tool for aiding clinical decision making. 
Rather than create a hierarchy of approaches, we advocate 
the use of a range of tools to aid decision making with 
due acknowledgement of their purpose, strengths and 
limitations.
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